Ignite Creation Date:
2025-12-25 @ 3:20 AM
Ignite Modification Date:
2026-03-02 @ 4:12 AM
Study NCT ID:
NCT00112905
Status:
TERMINATED
Last Update Posted:
2014-05-30
First Post:
2005-06-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adenocarcinoma of the Bladder | View |
| None | Distal Urethral Cancer | View |
| None | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | View |
| None | Proximal Urethral Cancer | View |
| None | Recurrent Bladder Cancer | View |
| None | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | View |
| None | Recurrent Urethral Cancer | View |
| None | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | View |
| None | Squamous Cell Carcinoma of the Bladder | View |
| None | Stage III Bladder Cancer | View |
| None | Stage IV Bladder Cancer | View |
| None | Transitional Cell Carcinoma of the Bladder | View |
| None | Urethral Cancer Associated With Invasive Bladder Cancer | View |
Keywords: